GlassScriptPhysician profile
Elizabeth Ruth Messulam
NPI 1922083252
$9,266.16
in general payments reported to CMS, 2019-2025
21 companies · $751 in 2025
The $751 reported for 2025 was more than what 77% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,765 · 2020: $542 · 2021: $1,543 · 2022: $1,987 · 2023: $1,514 · 2024: $1,164 · 2025: $751.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,429.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,429.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $1,791.45 | 2019-2024 | Aristada, Lybalvi, Aristada Initio |
| Ironshore Pharmaceuticals INC. | $1,353.06 | 2019-2024 | Jornay Pm |
| Otsuka America Pharmaceutical, INC. | $1,158.63 | 2019-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $1,137.18 | 2019-2024 | Invega Sustenna |
| Supernus Pharmaceuticals, INC. | $669.04 | 2021-2025 | Qelbree, Qelbree |
| Sunovion Pharmaceuticals INC. | $630.45 | 2019-2021 | |
| Abbvie INC. | $607.66 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $276.59 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $274.92 | 2024-2025 | Cobenfy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $268.85 | 2020-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $250.00 | 2024-2025 | Fanapt |
| Teva Pharmaceuticals USA, INC. | $245.38 | 2022-2024 | Uzedy |
| Axsome Therapeutics, INC. | $193.80 | 2023-2024 | Auvelity |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $143.87 | 2022-2023 | Rexulti, Abilify Maintena |
| Corium, LLC | $78.16 | 2021-2024 | Azstarys |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $62.03 | 2019-2020 | |
| Indivior INC. | $34.97 | 2022 | |
| Lundbeck LLC | $32.55 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.31 | 2019-2020 | |
| Collegium Pharmaceutical, INC. | $20.54 | 2025 | Jornay Pm |
| Jazz Pharmaceuticals INC. | $12.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Messulam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.